Patient Characteristics
| Characteristic | No RP (n = 122) | RP (n = 38) | P* |
|---|---|---|---|
| Age (y) | 67 (49–84) | 73 (45–86) | 0.10 |
| Sex | |||
| Female | 48 (39) | 17 (45) | 0.56 |
| Male | 74 (61) | 21 (55) | |
| Smoking history | |||
| Ever | 119 (98) | 35 (92) | 0.13 |
| During RT | 13 (11) | 0 (0) | 0.04 |
| Performance status | |||
| ECOG 0 | 65 (53) | 19 (50) | |
| ECOG 1 | 57 (47) | 19 (50) | 0.73 |
| AJCC eighth overall stage | |||
| IIIA | 31 (25) | 10 (26) | 0.20 |
| IIIB | 74 (61) | 16 (42) | |
| IIIC | 17 (14) | 12 (32) | |
| Diagnosed lung disease | |||
| Yes | 34 (28) | 33 (87) | 0.18 |
| COPD | 33 (27) | 15 (39) | |
| Asthma | 1 (1) | 2 (5) | |
| Diabetes mellitus | 27 (22) | 9 (24) | 0.84 |
| Histology | |||
| Adenocarcinoma | 68 (56) | 26 (68) | 0.14 |
| Squamous cell | 41 (34) | 11 (29) | |
| Other | 13 (11) | 1 (3) | |
| PDL1 expression | |||
| <1% | 39 (32) | 13 (34) | 0.83 |
| ≥1%-49 | 26 (21) | 8 (21) | |
| ≥50% | 31 (25) | 11 (29) | |
| Unknown | 26 (21) | 6 (16) | |
| Chemotherapy regimen | |||
| Carboplatin/paclitaxel | 56 (46) | 15 (39) | 0.61 |
| Carboplatin/pemetrexed | 32 (26) | 12 (32) | |
| Cisplatin/pemetrexed | 22 (18) | 7 (18) | |
| Cisplatin/etoposide | 10 (8) | 4 (11) | |
| Other | 2 (2) | — | |
| Days from cCRT end to Durvalumab start | 45 (10–234) | 41 (13–82) | 0.03 |
↵* Wilcoxon rank-sum test comparing characteristics between patients with and without RP.
ECOG = Eastern Cooperative Oncology Group; AJCC = American Joint Committee on Cancer; COPD = chronic obstructive pulmonary disease; PDL1 = programmed cell death ligand 1.
Qualitative data are number and percentage; continuous data are median and range.